Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19059608 | 0.92 | HDAC3 (0.40) | ABL1HDAC3HDAC1HDAC2MAPT | |
| SCHEMBL22018173 | 0.85 | MAPK1 (0.37) | ABL1HDAC3HDAC1HDAC2GLA | |
| SCHEMBL18399528 | 0.80 | MAPK1 (0.41) | ABL1HDAC3HDAC1HDAC2GLA | |
| SCHEMBL22018240 | 0.79 | MAPK1 (0.36) | ABL1HDAC3HDAC1HDAC2GLA | |
| SCHEMBL21157778 | 0.76 | HDAC3 (0.40) | ABL1HDAC3HDAC1HDAC2MAPT | |
| SCHEMBL22853622 | 0.76 | ABL1 (0.38) | ABL1MAPTGSK3BTSHRMEN1 | |
| SCHEMBL22853570 | 0.75 | PIM2 (0.43) | ABL1MAPTGSK3BSHMT2TSHR | |
| SCHEMBL19059694 | 0.75 | BCHE (0.46) | MAPT | |
| SCHEMBL19059705 | 0.73 | TSHR (0.40) | ABL1HDAC3HDAC1HDAC2GLA | |
| SCHEMBL20368738 | 0.73 | TSHR (0.40) | ABL1HDAC3HDAC1HDAC2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | ABL1 39/4885HDAC3 487/4885HDAC1 359/4885 |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | PIM2, PIM1, PIM3 | ABL1 39/4885HDAC3 487/4885HDAC1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.